Selected publications
-
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 5 -
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Cancer.
2017
Academic Article
GET IT
Times cited: 16 -
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
Clinical Lymphoma, Myeloma and Leukemia.
2017
Academic Article
GET IT
Times cited: 6 -
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Final results from the T- cell consortium trial.
British Journal of Haematology.
2016
Academic Article
GET IT
Times cited: 35 -
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
Hematological Oncology.
2016
Information Resource
GET IT
Times cited: 8 -
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study.
Journal of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 94 -
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Blood.
2012
Academic Article
GET IT
Times cited: 85 -
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.
Journal of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 349